Publication:

The RNA-binding protein ESRP1 promotes human colorectal cancer progression

Loading...
Thumbnail Image

Open/View Files

Date

2017

Journal Title

Journal ISSN

Volume Title

Publisher

Impact Journals LLC
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Fagoonee, S., G. Picco, F. Orso, A. Arrigoni, D. L. Longo, M. Forni, I. Scarfò, et al. 2017. “The RNA-binding protein ESRP1 promotes human colorectal cancer progression.” Oncotarget 8 (6): 10007-10024. doi:10.18632/oncotarget.14318. http://dx.doi.org/10.18632/oncotarget.14318.

Abstract

Epithelial splicing regulatory protein 1 (ESRP1) is an epithelial cell-specific RNA binding protein that controls several key cellular processes, like alternative splicing and translation. Previous studies have demonstrated a tumor suppressor role for this protein. Recently, however, a pro-metastatic function of ESRP1 has been reported. We thus aimed at clarifying the role of ESRP1 in Colorectal Cancer (CRC) by performing loss- and gain-of-function studies, and evaluating tumorigenesis and malignancy with in vitro and in vivo approaches. We found that ESRP1 plays a role in anchorage-independent growth of CRC cells. ESRP1-overexpressing cells grown in suspension showed enhanced fibroblast growth factor receptor (FGFR1/2) signalling, Akt activation, and Snail upregulation. Moreover, ESRP1 promoted the ability of CRC cells to generate macrometastases in mice livers. High ESRP1 expression may thus stimulate growth of cancer epithelial cells and promote colorectal cancer progression. Our findings provide mechanistic insights into a previously unreported, pro-oncogenic role for ESRP1 in CRC, and suggest that fine-tuning the level of this RNA-binding protein could be relevant in modulating tumor growth in a subset of CRC patients.

Description

Research Data

Keywords

ESRP1, RNA binding protein, proto-oncogene, human colorectal cancer

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Related Stories